Radiopharm Theranostics Limited
RADXHealthcare|Biotechnology|AU
$0.96
+0.07 (+7.85%)
Cash / Share
$0.35
Financials
Financial Snapshot
Market Cap
$1.2M
Enterprise Value
$5.3M
Revenue (TTM)
—
Net Income (TTM)
—
Cash & Investments
—
Net Cash
—
Free Cash Flow (TTM)
—
Operating CF (TTM)
—
Debt/Equity
0.00
Income Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $8.8K | $292.4K | $299.2K | $3.6M | $2.7M | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $3.6M | $4.8M | |
| Gross Profit | $8.8K | $292.4K | $299.2K | $39.3K | -$2.1M | |
| R&D | $4.1M | $13.8M | $17.6M | $27.5M | $0.00 | |
| SG&A | $10.8M | $13.0M | $15.2M | $16.5M | $15.9M | |
| Operating Income | -$19.9M | -$34.5M | -$36.6M | -$38.2M | -$66.8M | |
| Interest Expense | $9.3M | $86.1K | $642.9K | $65.3K | $109.9K | |
| Pretax Income | -$30.3M | -$34.6M | -$47.9M | -$38.2M | -$55.7M | |
| Net Income | -$30.3M | -$34.6M | -$47.9M | -$38.3M | -$53.9M | |
| EPS (Diluted) | -29.76 | -33.00 | -36.00 | -5.28 | -4.56 | |
| EBITDA | -$18.0M | -$31.2M | -$44.2M | -$35.5M | -$64.1M | |
| Shares Out. (M) | 1.02 | 1.02 | 1.29 | 6.94 | 11.81 |
Balance Sheet
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $27.0M | $11.7M | $18.6M | $29.1M | $4.1M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $27.3M | $16.3M | $22.8M | $39.9M | $21.9M | |
| Total Assets | $83.4M | $74.9M | $72.0M | $86.5M | $60.1M | |
| Total Current Liabilities | $7.9M | $13.2M | $17.6M | $14.9M | $18.9M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $20.4M | $29.4M | $44.7M | $43.6M | $37.8M | |
| Stockholders' Equity | $63.0M | $44.4M | $28.1M | $44.8M | $24.7M | |
| Retained Earnings | -$30.8M | -$65.4M | -$111.3M | -$145.7M | -$199.7M |
Cash Flow Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.9M | -$23.2M | -$23.0M | -$36.6M | -$51.6M | |
| Capital Expenditure | -$28.3M | -$1.5M | $0.00 | $0.00 | $51.6M | |
| Free Cash Flow | -$38.3M | -$24.7M | -$23.0M | -$36.6M | $0.00 | |
| Investing Cash Flow | -$28.4M | -$1.5M | -$320.0K | $1.8M | -$5.3M | |
| Financing Cash Flow | $65.1M | $9.2M | $30.2M | $45.4M | $32.6M | |
| Issuance of Stock | $70.0M | $10.1M | $29.6M | $54.0M | $32.6M | |
| Repurchase of Stock | -$4.8M | -$854.8K | -$1.5M | $0.00 | $0.00 | |
| Net Debt Issuance | -$59.0K | $0.00 | $2.2M | -$1.9M | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Change in Cash | $27.0M | -$15.3M | $6.9M | $10.5M | -$23.4M |
Dilution Tracker
Shares outstanding grew 1058.9% over 5 years — significant dilution
Shares Outstanding
1M
5-Year Share Growth
+1058.9%
Stock Issuance (2025)
$32.6M
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Shares Out. (M) | 1.02 | 1.02 | 1.29 | 6.94 | 11.81 | |
| Change vs Prior % | — | 0.0% | 26.4% | 438.5% | 70.3% | |
| Stock Issuance | $70.0M | $10.1M | $29.6M | $54.0M | $32.6M | |
| Stock Repurchase | -$4.8M | -$854.8K | -$1.5M | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Margins & Profitability
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 100.0% | 100.0% | 100.0% | 1.1% | -77.7% | |
| Operating Margin % | -225527.7% | -11803.3% | -12238.4% | -1050.6% | -2468.6% | |
| Net Margin % | -343550.9% | -11838.6% | -16024.3% | -1055.3% | -1992.5% | |
| EBITDA Margin % | -203396.2% | -10685.9% | -14773.8% | -976.3% | -2367.2% | |
| FCF Margin % | -433182.0% | -8459.6% | -7678.4% | -1008.6% | 0.0% | |
| ROE % | -48.2% | -78.0% | -170.5% | -85.6% | -218.5% | |
| ROA % | -36.4% | -46.2% | -66.6% | -44.3% | -89.7% | |
| ROIC % | -26.4% | -55.9% | -67.2% | -53.4% | -161.9% | |
| R&D / Revenue % | 46707.6% | 4720.4% | 5868.2% | 757.3% | 0.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0.0% | 3210.6% | 2.3% | 1114.3% | -25.5% | |
| Gross Profit | 0.0% | 3210.6% | 2.3% | -86.9% | -5454.2% | |
| Operating Income | 0.0% | -73.3% | -6.1% | -4.2% | -75.1% | |
| Net Income | 0.0% | -14.1% | -38.5% | 20.0% | -40.7% | |
| EPS (Diluted) | 0.0% | -10.9% | -9.1% | 85.3% | 13.6% | |
| Operating Cash Flow | 0.0% | -134.0% | 1.0% | -59.5% | -40.9% | |
| Free Cash Flow | 0.0% | 35.3% | 7.1% | -59.5% | 100.0% | |
| R&D Expense | 0.0% | 234.6% | 27.2% | 56.7% | -100.0% | |
| SG&A Expense | 0.0% | 20.0% | 16.9% | 8.6% | -4.0% | |
| Total Assets | 0.0% | -10.1% | -3.9% | 20.1% | -30.5% | |
| Book Value / Share | 0.0% | -27.6% | -52.5% | -70.9% | -69.4% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | 26.4% | 438.5% | 70.3% |
Valuation
P/E (TTM)At Loss
P/S3.42
10Y Low / Med / High13.46 / 92.46 / 2954.46
P/B0.57
10Y Low / Med / High0.41 / 1.09 / 2.90
EV/EBITDAAt Loss
EV/Revenue1.92
10Y Low / Med / High5.45 / 52.12 / 52.45
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$0.35
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| P/E Ratio | -0.86 | -0.80 | -0.74 | -1.34 | -1.33 | |
| P/S Ratio | 2954.46 | 92.46 | 114.19 | 13.46 | 26.42 | |
| P/B Ratio | 0.41 | 0.61 | 1.22 | 1.09 | 2.90 | |
| EV/EBITDA | 0.05 | -0.49 | -0.35 | -0.56 | -1.05 | |
| EV/Revenue | -100.58 | 52.45 | 52.12 | 5.45 | 24.89 |
Analyst Estimates & Quality
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 | FY2029 |
|---|---|---|---|
| Revenue | $2.2M | $2.7M | $83.6M |
| Net Income | -$37.2M | -$36.0M | -$7.3M |
| EPS | $-3.15 | $-3.04 | $-0.62 |
| # Analysts (EPS) | 1 | 1 | 1 |
Revenue Segments
By Geography
| Segment | 2024 | 2025 |
|---|---|---|
| UNITED STATES | $3.6M | $2.8M |